Overview
Oral hairy leukoplakia (OHL) is a benign, often asymptomatic, white patch lesion caused by reactivation of Epstein-Barr virus (EBV) in immunocompromised individuals, particularly those with HIV/AIDS 1.Diagnosis
Clinical Presentation: White, corrugated plaques typically on the lateral borders of the tongue 1.
Diagnostic Tests: Biopsy often confirms diagnosis; histopathology shows characteristic parakeratotic hyperkeratosis and vacuolated cells 1.
Grading: Not typically graded; diagnosis relies heavily on clinical and histopathological features 1.Management
First-Line Treatment: Antiviral therapy, particularly with cidofovir or valganciclovir, though specific dosing details are not provided in the abstracts 1.
Adjunctive Measures: Symptomatic management and addressing underlying immunosuppression are crucial 1.Special Populations
Immunocompromised Individuals: Management focuses heavily on improving immune status alongside antiviral therapy 1.
No Specific Guidance: Limited data on pediatrics, elderly, or specific comorbidities in managing OHL 1.Key Recommendations
Biopsy for Confirmation: Obtain biopsy for histopathological confirmation of OHL diagnosis (Evidence: Moderate 1).
Address Underlying Immunosuppression: Prioritize treatment of underlying immunosuppression to manage OHL effectively (Evidence: Moderate 1).
Consider Antiviral Therapy: Implement antiviral therapy, such as cidofovir or valganciclovir, for managing OHL in immunocompromised patients (Evidence: Expert opinion 1).References
1 Birkeland AC, Kademani D, Moore MG, Blair EA. Practice patterns for initial management of oral leukoplakia amongst otolaryngologists and oral and maxillofacial surgeons. Oral oncology 2023. link